Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Examining How Chronic Health States and Acute Treatment Contribute to Variations in AMI Mortality Across the English NHS

Condition:   Myocardial Infarction
Intervention:   Other: Standard Hospital Care
Sponsor:   London School of Economics and Political Science
Active, not recruiting - verified February 2015

Benefits of Exercise Training in Women With Ischemic Syndrome

Condition:   Microvascular Coronary Dysfunction
Intervention:   Behavioral: Exercise training
Sponsor:   Cedars-Sinai Medical Center
Not yet recruiting - verified February 2015

Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

Conditions:   Peripheral Pulmonary Stenosis;   In-stent Stenosis
Intervention:   Drug: Sirolimus
Sponsor:   Children's Hospital Boston
Recruiting - verified February 2015

A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries

Condition:   Deep Vein Thrombosis
Intervention:   Drug: Sodium Enoxaparine
Sponsor:   Biocad
Recruiting - verified January 2015

Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy

Condition:   Ischemic Cardiomyopathy
Interventions:   Biological: WJMSCs  Vs. placebo;   Biological: Placebo
Sponsors:   Navy General Hospital, Beijing;   First people's Hospital of Foshan, Beijing;   General Hospital of Armed Police, Beijing;   PLA General Hospital, Beijing
Not yet recruiting - verified January 2015

Production of a Patient-specific Simulator for Endovascular Aneurysm Repair Training

Condition:   Aneurysm
Intervention:   Procedure: Training
Sponsor:   University of Sao Paulo General Hospital
Recruiting - verified January 2015

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Conditions:   Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions:   Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Not yet recruiting - verified February 2015

Efficacy and Safety on Prouk for STEMI Patients in China

Condition:   STEMI
Intervention:   Drug: rhprouk
Sponsor:   Suzhou RxD Biopharmaceutical Co., Ltd
Recruiting - verified February 2015

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Not yet recruiting - verified February 2015

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Condition:   Cardiogenic Shock
Intervention:   Device: HeartMate PHP
Sponsor:   Thoratec Corporation
Recruiting - verified February 2015

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2015

Rituximab and Belimumab for Lupus Nephritis

Condition:   Lupus Nephritis
Interventions:   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Recruiting - verified February 2015

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction

Conditions:   ST-segment Elevation Myocardial Infarction;   Non-ST-segment Elevation Myocardial Infarction;   VA Drug Interactions [VA Drug Interaction]
Interventions:   Drug: Morphine;   Drug: Placebo;   Drug: Ticagrelor
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified February 2015

HeartMate III™ IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate III LVAS;   Device: HeartMate II LVAS
Sponsor:   Thoratec Corporation
Recruiting - verified February 2015

Drug Eluting Ballon Versus Stenting in the Superficial Femoral Artery

Condition:   Superficial Femoral Artery Stenosis
Interventions:   Device: Drug Eluting Balloon Angioplasty;   Device: Nitinol stenting
Sponsors:   Instituto Dante Pazzanese de Cardiologia;   Medtronic
Recruiting - verified February 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2015

Comparison Between Moderate-high Interval Exercise and Moderate Continuous Exercise in an Advanced Cardiac Rehabilitation Program

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Interventions:   Other: Interval exercise training;   Other: Continuous exercise training
Sponsor:   Assaf-Harofeh Medical Center
Recruiting - verified February 2015

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Conditions:   Heart Transplant;   Liver Transplant;   Small Intestine Transplant;   Lymphoproliferative Disorders;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder
Interventions:   Procedure: transplant;   Drug: Immunosuppressive Drugs
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation in Children (CTOT-C)
Recruiting - verified February 2015

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified February 2015

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Condition:   ST-Segment Elevation Myocardial Infarction
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   Jinan Central Hospital
Not yet recruiting - verified February 2015

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

Condition:   Congestive Heart Failure
Intervention:   Device: Samsung LABGEO IVD-A20 CHF Test
Sponsors:   Samsung Electronics;   Nexus-Dx
Terminated - verified February 2015

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   HIV Infection
Interventions:   Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2014

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified February 2015

Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol

Conditions:   Aortic Valve Disease;   Coronary Artery Disease (CAD)
Interventions:   Drug: Custodiol-N;   Drug: Custodiol
Sponsor:   Dr. F. Köhler Chemie GmbH
Recruiting - verified February 2015

Understanding the Exercise-Hypertension Paradox

Condition:   Hypertension
Interventions:   Dietary Supplement: Oral Antioxidant;   Other: Exercise rehabilitation
Sponsor:   Department of Veterans Affairs
Recruiting - verified February 2015

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

Study of BioNIR Drug Eluting Stent System in Coronary Stenosis

Condition:   Coronary Artery Stenosis
Interventions:   Device: BioNIR;   Device: Resolute
Sponsor:   Medinol Ltd.
Recruiting - verified February 2015

Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study

Condition:   Hip Fractures
Intervention:  
Sponsor:   Population Health Research Institute
Active, not recruiting - verified February 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2015

Prophylactic IABP in High-risk Patients Undergoing CABG

Conditions:   Myocardial Infarction;   Coronary Artery Disease
Intervention:   Procedure: Preoperative IABC
Sponsor:   University of Giessen
Not yet recruiting - verified February 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified February 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified February 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified February 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified February 2015

The TRUST Study - Depression Substudy

Conditions:   Subclinical Hypothyroidism;   Depression
Interventions:   Drug: Levothyroxine;   Drug: Placebo
Sponsors:   University Hospital Inselspital, Berne;   Leiden University Medical Center;   University of Bern
Recruiting - verified February 2015

Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery

Conditions:   High Risk Non-cardiac Surgery;   Death;   Delirium;   Kidney Injury;   Myocardial Infarction;   Respiratory Failure;   Postoperative Infection
Intervention:   Other: Observational study
Sponsors:   University of Manitoba;   Canadian Anesthesia Research Foundation
Recruiting - verified February 2015

Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease
Intervention:   Device: Drug-eluting stent
Sponsor:   Odense University Hospital
Recruiting - verified February 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified February 2015

Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib

Condition:   Leukemia
Intervention:   Drug: Ponatinib
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Active, not recruiting - verified February 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease

Conditions:   Myocardial Infarction;   Unstable Angina
Intervention:  
Sponsors:   Massachusetts General Hospital;   University of California, Berkeley
Completed - verified February 2015

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified February 2015

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2015

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Condition:   Leukemia
Intervention:   Drug: Ponatinib
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Recruiting - verified February 2015

Primary Reperfusion Secondary Stenting Trial

Condition:   ST-elevation Myocardial Infarction
Intervention:   Procedure: Percutaneous coronary intervention
Sponsor:   Montreal Heart Institute
Recruiting - verified February 2015

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Modification of Prasugrel based on a biological assay;   Drug: prasugrel / clopidogrel;   Device: Verify Now
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Allies in Cardiovascular Trials Initiatives and Organized Networks:ACTION;   Accumetrics, Inc.;   Stentys
Recruiting - verified February 2015

"ESTIMATION Study" for Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Heart Failure
Intervention:   Procedure: PCI and Stem Cells or Placebo injections
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Drug: Aspirin 200mg qd, Clopidogrel 2x75mg qd
Sponsor:   University Hospital Ostrava
Recruiting - verified February 2015

The Natural History of Graft-Versus-Host Disease in the Eyes

Condition:   Graft-Versus-Host Disease
Intervention:  
Sponsor:   National Eye Institute (NEI)
Recruiting - verified February 2015

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.

Conditions:   Atrial Fibrillation;   Peripheral Vascular Disease
Intervention:  
Sponsor:   University of Roma La Sapienza
Completed - verified February 2015

Anticoagulation in Stent Intervention

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid  + clopidogrel
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting - verified February 2015

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

Aerobic Interval Training in Cardiac Rehabilitation

Conditions:   Myocardial Infarction;   Coronary Artery Disease
Intervention:   Other: Exercise training
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed - verified February 2015

Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease

Conditions:   Myocardial Ischemia;   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2015

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified February 2015

French Registry of Acute Coronary Syndrome

Condition:   Acute Myocardial Infarction
Intervention:   Other: Blood sample
Sponsors:   Assistance Publique - Hôpitaux de Paris;   French Cardiology Society
Active, not recruiting - verified October 2014

Study of Late-Occurring Complications in Childhood Cancer Survivors

Conditions:   Cancer Survivor;   Cardiovascular Complications;   Hematopoietic/Lymphoid Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2015

Diagnosis of Pheochromocytoma

Condition:   Pheochromocytoma
Intervention:  
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2015

Get CardioSmart

You're Invited